SurModics. has filed a patent for thromboresistant coatings for medical devices. The patent describes a device with a substrate, a non-fouling basecoat layer containing hydrophilic and hydrophobic components, and a lubricious topcoat layer with a photo-reactive polyvinylpyrrolidone compound and a cross-linking agent. The device can be implantable, partially implantable, or wearable. GlobalData’s report on SurModics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on SurModics, bioresorbable stent coating was a key innovation area identified from patents. SurModics's grant share as of September 2023 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Thromboresistant coating for medical devices
A recently filed patent (Publication Number: US20230285641A1) describes a thromboresistant implantable, partially implantable, or wearable medical device. The device consists of a substrate and two layers: a non-fouling basecoat layer and a lubricious topcoat layer.
The non-fouling basecoat layer is made up of a hydrophilic component and a hydrophobic component. The hydrophilic component is a polyvinylpyrrolidone polymer, which may be cross-linked with an acrylamide polymer. The hydrophobic component is a poly(n-butyl methacrylate). The ratio of the hydrophobic component to the hydrophilic component in the non-fouling basecoat layer is between 2.5:1 and 3.5:1 by weight. Additionally, the non-fouling basecoat layer may contain a heparin compound.
The lubricious topcoat layer consists of a photo-reactive polyvinylpyrrolidone compound and a cross-linking agent. This layer is applied over the non-fouling basecoat layer. The lubricious topcoat layer may also contain a polyacrylamide polymer, a polyzwitterion, or an anionic polymer. Furthermore, it may include a first layer and a second layer, with the second layer being different from the first layer. The lubricious topcoat layer may also contain an elutable antiplatelet macromer or a non-prodrug anti-platelet agent.
The patent claims also mention the use of a heparin compound in both the non-fouling basecoat layer and the lubricious topcoat layer. The heparin compound may have a photoreactive group and can be cross-linked with the photo-reactive polyvinylpyrrolidone compound. In some embodiments, the heparin compound may be ionically complexed with a polycationic polymer such as PEI, PHEMA-co-DMAEMA, or PEG-DMAEMA.
Overall, this patent describes a medical device with a thromboresistant coating that combines hydrophilic and hydrophobic components in the basecoat layer and a photo-reactive polyvinylpyrrolidone compound in the lubricious topcoat layer. The inclusion of heparin compounds and other polymers in the topcoat layer enhances the device's ability to resist blood clot formation.
To know more about GlobalData’s detailed insights on SurModics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
